Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Francis Steltz on Sep 18th, 2026

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $365.40.

A number of analysts have recently issued reports on KRYS shares. Citigroup lifted their price target on Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. HC Wainwright raised their price objective on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday, June 16th. Royal Bank Of Canada assumed coverage on shares of Krystal Biotech in a research note on Friday, August 14th. They set an “outperform” rating and a $400.00 target price on the stock. Finally, Bank of America upped their target price on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th.

View Our Latest Stock Analysis on KRYS

Insider Transactions at Krystal Biotech

In related news, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This represents a 33.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John Thomas sold 1,000 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares of the company’s stock, valued at approximately $347,270. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 51,000 shares of company stock valued at $17,558,270. Corporate insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KRYS. Handelsbanken Fonder AB lifted its position in Krystal Biotech by 58.4% during the fourth quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock worth $26,084,000 after buying an additional 39,000 shares in the last quarter. Fisher Asset Management LLC purchased a new stake in Krystal Biotech in the 4th quarter valued at $933,000. William Blair Investment Management LLC grew its holdings in Krystal Biotech by 152.1% in the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after buying an additional 227,038 shares in the last quarter. Biondo Investment Advisors LLC grew its holdings in Krystal Biotech by 31.3% in the 4th quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock valued at $16,797,000 after buying an additional 16,245 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Krystal Biotech by 36.6% in the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock worth $67,330,000 after acquiring an additional 69,840 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Up 0.6%

Shares of NASDAQ KRYS opened at $338.75 on Friday. The firm has a market cap of $10.03 billion, a price-to-earnings ratio of 42.45 and a beta of 0.54. The company’s 50-day simple moving average is $344.63 and its 200-day simple moving average is $312.11. Krystal Biotech has a 52-week low of $155.20 and a 52-week high of $382.54.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The business had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. Equities research analysts anticipate that Krystal Biotech will post 7.48 EPS for the current fiscal year.

About Krystal Biotech

(Get Free Report)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.